(514) 393-1055

Molecular Operating Environment (MOE™) Users Enjoy the Power of IBM Systems

MONTREAL, Dec. 19, 2003

The combination of Chemical Computing Group's Molecular Operating Environment (MOE™) with IBM's comprehensive range of hardware platforms is proving a powerful one in addressing problems in the drug discovery industry. MOE has long been available on Linux and Windows, but an agreement between CCG and IBM brought the power of MOE to AIX® Unix systems, alongside support for MOE on IBM's powerful Linux cluster and Intellistation® hardware products. MOE users are now enjoying the widest possible choice of platforms, and benefiting from the speed and graphics capabilities of IBM's pSeries® and xSeries® hardware. MOE is also now capable of interacting with IBM's DB2® database software platform.

"I am having a very positive experience running MOE on an IBM Intellistation® M-PRO under Linux," said Dr. Vincenzo Tschinke of Speedel Group, a biopharmaceutical company based in Basel, Switzerland, speaking on December 10th 2003. "The very responsive graphics and computational power of this combination has allowed me to fully analyze close to a thousand molecules in three dimensions -- including docking to protein binding sites and the creation of predictive QSAR models -- in less than a year. The workstation has been running error-free for over 300 days".

Now that the benefits of the collaboration are becoming clear, CCG and IBM intend to continue to work together to enhance the efficiency and productivity of drug discovery researchers.

About CCG
Chemical Computing Group Inc. is a leading provider of computational applications aimed at the drug discovery and design marketplace. CCG's flagship product is the award winning Molecular Operating Environment (MOE), which offers visualization, simulation, and methodology development in one package. MOE provides an integrated suite of powerful, yet intuitive chemistry software tools for HTS, structure-based design, molecular modeling, protein and homology modeling, as well as an embedded programming language for the rapid prototyping of scientific methods. Computational chemists, medicinal chemists and biologists use MOE in pharmaceutical companies, biotechnology companies, and universities worldwide. CCG is located in Montreal. Its web site is www.chemcomp.com. E-mail inquiries can be sent to .

About Speedel
The Speedel Group, based in Basel, Switzerland, is a biopharmaceutical company with a core competence in drug development, focusing on early proof-of-concept in man in cardiovascular and metabolic diseases. These are the main causes of death in the industrialized world and represent the largest pharmaceutical market segments worldwide. A privately owned company formed in 1998, Speedel employs a team of over forty experienced pharmaceutical scientists and managers in Europe, the United States and Japan. Speedel in-licenses innovative drug candidates at late preclinical or early clinical development stages and upon completion of proof-of-concept in man at Phase II, Speedel partners with leading pharmaceutical companies for Phase III development and commercialization. In addition, Speedel is a world-leader in the area of renin inhibitors and through its research unit Speedel Experimenta it generates novel development candidates and new Intellectual Property. For additional information see www.speedelgroup.com.

"MOE" is a trademark of Chemical Computing Group Inc.
"AIX", "DB2", "pSeries", "xSeries" and "Intellistation" are registered trademarks of IBM.